We investigated the effects of aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril on left ventricular mass (LVM) index and arterial stiffness in hypertensive type II diabetic individuals. Seventy hypertensive type II diabetic individuals were treated with three antihypertensive strategies in a randomized, double-blind, double-dummy design. Blood pressure was titrated to levels below 130/ 85 mm Hg or a decrease in systolic pressure of 10% with a diastolic pressure below 85 mm Hg. After titration, patients were treated for 12 months. Mean blood pressures were 157/93, 151/94 and 149/93 mm Hg at baseline in the hydrochlorothiazide (n ¼ 24), candesartan (n ¼ 24) and lisinopril (n ¼ 22) groups, and 135/80, 135/82 and 131/80 mm Hg after titration. About 70% reached target blood pressures, with the median use of three antihypertensive drugs. Left ventricular mass index and all estimates of arterial stiffness showed significant improvement after 12 months: that is, LVM index (À11 g/m 2 ; À8%); carotid distensibility coefficient (DC; þ 2.8 Â 10 À3 kPa À1 ; þ 27%), compliance coefficient (CC; þ 0.13 mm 2 /kPa; þ 21%) and elastic modulus (À0.19 kPa; À16%); femoral DC ( þ 1.6 Â 10 À3 kPa À1 ; þ 50%) and CC ( þ 0.08 mm 2 /kPa; þ 26%); brachial DC ( þ 2.1 Â 10 À3 kPa À1 ; þ 39%) and CC ( þ 0.03 mm 2 /kPa; þ 27%) and total systemic arterial compliance ( þ 0.29 ml/mm Hg; þ 16%). No differences in outcome variables between treatment groups were observed. Aggressive antihypertensive treatment, although difficult to achieve, resulted in substantial reductions of LVM index and arterial stiffness in relatively uncomplicated hypertensive type II diabetic individuals. Strategies based on renin-angiotensin system inhibitors were not clearly superior to conventional (i.e. diuretic-based) strategies.
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Introduction
Risk of cardiovascular disease is extremely high in individuals with both type II diabetes and hypertension, such that up to 80% of such patients will die of myocardial infarction, stroke or peripheral arterial disease. 1, 2 Hypertension control in these patients substantially reduces cardiovascular risk, 3 and current guidelines therefore recommend aggressive treatment of hypertension in type II diabetes.
It remains controversial whether in type II diabetes and at the same level of blood pressure control, an antihypertensive strategy that includes renin-angiotensin system inhibitor is superior to one that does not include such drugs. [4] [5] [6] [7] [8] [9] [10] Any bloodpressure-independent benefits of angiotensin converting enzyme (ACE) inhibitors and angiotensin II type 1 (AT1) receptor antagonists are clinically relevant only if they remain during aggressive antihypertensive therapy. Comparison of these drugs with conventional (i.e. diuretic-based) initial treatment in the context of an aggressive antihypertensive strategy is thus important.
Key mechanisms through which antihypertensive drugs may exert their beneficial effects include reduction of left ventricular hypertrophy and arterial stiffness, which are therefore considered important intermediate end points for hypertensionrelated cardiovascular complications. [11] [12] [13] In addition, it has been suggested that left ventricular hypertrophy and arterial stiffness are more effectively reduced by renin-angiotensin system inhibitors than by diuretics 14, 15 because ACE inhibitors and AT1 receptor antagonists may reverse structural changes of myocardium and large arteries 16 by inhibition of myocardial and vascular growth factors. However, the effects of aggressive antihypertensive strategies on left ventricular hypertrophy and arterial stiffness in type II diabetes (which itself is a risk factor for these conditions) have not been studied.
In view of these considerations, we investigated the effects of aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril on left ventricular mass (LVM) index and arterial stiffness in relatively uncomplicated hypertensive type II diabetic individuals.
Methods
Between July 1998 and October 2001, a randomised, double-blind, double-dummy, intervention study of patients with type II diabetes mellitus and hypertension was performed in the outpatient clinic of the VU University Medical Center, Amsterdam, and five other hospitals in the same region.
Patients
Patients were recruited from Internal Medicine outpatient clinics and by newspaper advertisements. Inclusion criteria for the run-in period were type II diabetes mellitus for X6 months (WHO criteria 1985), 17, 18 age between 35 and 70 years, Caucasian ethnicity and urinary albumin excretion o100 mg/24 h. Individuals were excluded in case of pregnancy or planning pregnancy, a history of myocardial infarction, angina pectoris, coronary artery bypass surgery, angioplasty, stroke, congestive heart failure, malignancy or other serious illnesses, serum creatinine 4140 mmol/l, use of antihypertensive medication in the previous month or ACE inhibitors in the previous 3 months, body mass index 435 kg/m 2 , alcohol and/or drug abuse, or participation in other clinical trials. The protocol was approved by the appropriate medical ethics committees.
Study protocol
The study consisted of three periods: a 1-month runin period, a 4-6-month blood pressure titration phase and a 12-month continued treatment phase. Figure 1 shows the time points when measurements were taken. Eligible patients entered into the run-in period on a 100 mmol/24 h sodium-containing diet without any antihypertensive drugs. Patients with a sitting blood pressure above 140/90 mm Hg and below 190/120 mm Hg (mean of three consecutive office measurements after 5 min of seated rest) after the run-in period had an echocardiography. If the LVM index was 490 g/m 2 (men) or 470 g/m 2 (women), the patient was included.
Patients were randomized to receive once daily treatment with 12.5 mg hydrochlorothiazide, 8 mg candesartan or 10 mg lisinopril. This procedure was performed according to a randomization list generated using a computer program at Astra Hässle, Sweden. Block randomization of six individuals per clinic was used. Enrolment and patient numbers were allocated consecutively. In order to maintain a double-blind character throughout, each patient received, besides the allocated intervention, placebo tablets for the other two study medications. After randomization, the titration period started. The aim of this period was to achieve a sitting blood pressure below 130/85 mm Hg, or a sitting systolic blood pressure decrease of more than 10% combined with a sitting diastolic blood pressure below 85 mm Hg. If necessary, additional therapy was administered according to a strict non-blinded protocol as described in Figure 2 . We thus co-administered hydrochlorothiazide in all three groups. This implies that the candesartan and lisinopril groups were treated with both a diuretic and an inhibitor of the renin-angiotensin system, giving candesartan and lisinopril an optimal chance to show their beneficial effects over those of hydrochlorothiazide-based therapy. Levels of potassium were determined at every visit, and when levels were low (o3.5 mmol/l) amiloride was administered. The 12-month study phase started when target blood pressures had been achieved or, if not, when the end of the titration schedule shown in Figure 2 had been reached. We measured blood pressure and pulse rate, and did echocardiography and vascular function and laboratory measurements at baseline and after 6 and 12 months of treatment. All measurements (Figure 1 ), except for ambulatory blood pressure, were performed on a single morning (0800-1300). Food, caffeine-containing beverages and smoking were not allowed from 2200 the night before. First, blood samples were collected. Then the participants were allowed a light low-fat meal without caffeinecontaining beverages. Next, we measured weight Figure 2 Antihypertensive strategies, and the number of individuals in each step. The steps in grey were performed in a double-blind fashion. *When contra-indications for calcium antagonists, b-blockers or a-blockers were present or side effects occurred, relevant steps were skipped.
and height. Body mass index was calculated as weight divided by height 2 . Subsequently, we measured blood pressure and carried out vascular ultrasound examinations.
Ambulatory blood pressure monitoring Ambulatory blood pressure monitoring (Spacelabs 90207, Spacelabs Medical Inc., Redmond, WA, USA) was used to obtain 24 h recordings of blood pressure and heart rate at baseline and 12 months. Blood pressure and heart rate were determined at 15 min intervals between 0700 and 2200, and at 20 min intervals from 2200 to 0700. From the ambulatory measurements, we calculated mean systolic, diastolic and mean blood pressure. Pulse pressure was calculated as mean systolic minus mean diastolic blood pressure. Waking and sleeping blood pressures were calculated using a diary kept by the patients during the 2 days of the measurement.
Echocardiography
An experienced research technician unaware of the patients' medication obtained an echocardiogram according to a standardized protocol, with the use of a single ultrasound scanner (HP SONOS 5500, Andover, MA, USA). M-mode recordings were digitally stored and read according to the guidelines of the American Society of Echocardiography. 19 Left ventricular end-diastolic diameter (EDD), posterior wall thickness (PWT) and the interventricular septum thickness (IVS) were measured at end diastole. Left ventricular mass was calculated as: 20, 21 and LVM index as LVM divided by body surface area (BSA). Each echocardiogram was inspected afterwards by a senior cardiologist blinded to the participants' medication to monitor the quality of both recordings and readings.
Arterial stiffness
We obtained estimates of peripheral and central arterial stiffness, as described in detail elsewhere. [22] [23] [24] Briefly, we measured distensibility and compliance of the carotid, the femoral and the brachial arteries, Young's elastic modulus of the carotid artery and total systemic arterial compliance. These measurements were performed by use of an ultrasound scanner (Pie350 scanner, (linear array, 7.5 MHz transducer), Pie Medical BV, Maastricht, The Netherlands) that was connected to a PC equipped with vessel wall movement detection software and an acquisition system (Wall Track System, Pie Medical).
General procedures. Brachial artery systolic, mean and diastolic blood pressures were recorded at the left upper arm at 5 min intervals using an oscillometric blood pressure measuring device (Colin Press-Mate BP-8800, Colin, Komaki-City, Japan). These blood pressure measurements were performed during vascular ultrasound and tonometry, and used for the calculation of the arterial distensibility and compliance coefficients and total systemic arterial compliance (see below).
Arterial stiffness: right common carotid, common femoral and brachial artery distensibility and compliance coefficients (DC and CC), carotid Young's elastic modulus (Ey) and total systemic arterial compliance (SAC).
Both DC and CC are indices of elasticity and therefore inversely related to stiffness. Distensibility coefficients describes intrinsic vessel wall stiffness, whereas CC is a measure of the capacity of the vessel to buffer the pulsatile cardiac load. Carotid Young's elastic modulus reflects the elastic properties of the vessel wall material.
We calculated DC, CC and Ey from measured arterial diastolic diameter (D; in mm), distension (i.e., difference between systolic and diastolic diameters (dD); in mm), pulse pressure (PP) and intima-media thickness (IMT; in mm). 23 We used brachial PP as an estimate of carotid, femoral and aortic PP, which is a reasonable approximation in elderly hypertensive individuals. 25 Distensibility coefficient, CC and Ey were calculated as follows:
Total SAC is inversely related to stiffness of mainly the proximal aorta. Total SAC was determined by use of the ratio of stroke volume to aortic PP (in ml per mm Hg), where stroke volume was calculated as cardiac output/heart rate and aortic PP was estimated from brachial PP. Coefficients of variation were: diameters, 1.5% (carotid), 2.5% (femoral) and 4.3 % (brachial); distension, 2.9% (carotid), 11.6% (femoral) and 12.8% (brachial); DC, 7.0% (carotid), 11.3% (femoral) and 12.8% (brachial); CC, 6.3% (carotid), 13.1% (femoral) and 13.9% (brachial); carotid elastic modulus, 11.6% and SAC, 8.3%.
Laboratory analyses
Glycated haemoglobin (HbA1c) was determined by high-performance liquid chromatography (Bio-Rad Laboratories BV, Veenendaal, The Netherlands). Serum and urine creatinine were determined by a modified Jaffé method. Urinary albumin excretion (mg/24 h) was measured with immunonephelometry (Array Protein System, Beckham Instruments, Brea, CA, USA). Total cholesterol, triglycerides and HDLcholesterol were measured by enzymatic techniques (Boehringer-Mannheim, Mannheim, Germany) and LDL-cholesterol was calculated with the Friedewald formula.
Statistical analyses
We aimed to include 38 patients in each group to have a 90% probability to detect a true mean difference in the change of LVM index of 15 g/m 2 (assumed s.d., 20 g/m 2 ) and in carotid DC of 2.5 Â 10 À3 /kPa (assumed s.d., 0.8 Â 10 3 /kPa) between the treatment groups at a ¼ 0.05. However, owing to laborious inclusion, we had to stop inclusion before reaching the planned number of patients. The data are expressed as mean7s.d., or as median (range). We used generalized estimating equation (GEE) analyses 27 to investigate changes in LVM index and arterial stiffness over time in the whole group. In these analyses, the values at 6 and 12 months were used as outcome, whereas the values of the variable under consideration measured one time-point earlier were used as covariate. To investigate whether the development over time for a particular variable was dependent on the blood pressure decrease, we adjusted LVM index for systolic blood pressure, and arterial stiffness for mean arterial blood pressure in additional models. Next, we investigated whether the changes in LVM index were mediated by changes in arterial stiffness. Finally, we investigated differences between the three treatment groups. A two-tailed Po0.05 was accepted as the level of significance. Standard statistical analyses were performed with SPSS 9.0 for windows. Generalised estimating equation analyses were performed with STATA (version 7).
Results
Seventy patients with type II diabetes mellitus and hypertension were randomized to treatment with hydrochlorothiazide (24) , candesartan (24) or Table 1 Baseline characteristics
Clinical characteristics Age (years) 63 (6) 60 (7) 62 (8) Data on LDL-cholesterol were missing in two individuals in the hydrochlorothiazide group owing to triglyceride levels being above 5.0 mmol/l.
lisinopril (22) . One patient was lost to follow-up and nine patients discontinued intervention. Reasons for drop-out were epigastric pain (1), aortic surgery (1), difficulties to swallow study medication (1) and myocardial infarction (2) in the hydrochlorothiazide group palpitations (1), dizziness (1), development of macroalbuminuria (1) and withdrawal for unspecified reasons (1) in the candesartan group; and a rise in creatinine levels (1) in the lisinopril group. Table 1 shows the clinical characteristics at baseline. No differences in baseline characteristics between the treatment groups were observed, except that systolic blood pressure was slightly higher in the hydrochlorothiazide group. Individuals who discontinued the study were not different in baseline characteristics from those who continued, except that they had higher triglyceride levels (data not shown). Figure 2 shows the antihypertensive strategies to achieve target blood pressures and the number of individuals in each step. Figure 3 shows a CONSORT flow diagram of the individuals through each stage of the study. Figure 4 ).
Left ventricular mass index. The LVM index decreased significantly, by 5 g/m 2 (5%) after 6 months and 11 g/m 2 (8%) after 12 months, as compared to baseline (Table 2, Figure 5 ).
Arterial stiffness. Arterial stiffness showed significant improvement on all estimates: carotid DC ( þ 2.8 Â 10
À3 kPa À1 ; þ 27%), CC ( þ 0.13 mm 2 /kPa; þ 21%) and Ey (À0.19 kPa; À16%); femoral DC ( þ 1.6 Â 10 À3 kPa À1 ; þ 50%) and CC ( þ 0.08 mm 2 / kPa; þ 26%); brachial DC ( þ 2.1 Â 10 À3 kPa À1 ; þ 39%) and CC ( þ 0.03 mm 2 /kPa; þ 27%) and total SAC ( þ 0.29 ml/mm Hg; þ 16%). This was related mainly to increases in arterial distension. Owing to logistic problems, femoral artery parameters after 12 months of treatment could only be measured in 45 patients (Table 2, Figure 6 ).
Comparison of the effects of hydrochlorothiazide-, candesartan-and lisinopril-based strategies Blood pressure. Overall, 75, 67 and 68% achieved the blood pressure goals after the titration phase, with the median use of four, three and three antihypertensive drugs in the hydrochlorothiazide (daily median dose, 25 mg), candesartan (16 mg) and lisinopril groups (20 mg), respectively ( Figure 2 ). Both sitting systolic and diastolic blood pressure decreased significantly between baseline and 6 and 12 months in all treatment groups (Figure 4) , whereas no differences between treatment groups were observed ( Complete follow-up (n=20) Incomplete follow-up (n=4) Figure 3 CONSORT flow diagram. Individuals who discontinued did that before (9), or directly after the 6-month measurement (1) .
by 6% at 6 months and remained stable between 6 and 12 months. In both the candesartan and lisinopril groups, LVM index decreased by 4% at 6 months and by 10% at 12 months. This difference between the hydrochlorothiazide group and the candesartan and lisinopril groups was not significant at either time point ( Figure 5 , Table 3 ). Figure 5 suggests that it cannot be excluded that the effect of hydrochlorothiazide on LVM index reaches its maximum already at 6 months, whereas the effect of candesartan and lisinopril continues at 12 months.
In an additional GEE analysis, we combined the candesartan and lisinopril groups. As compared to the hydrochlorothiazide group, the change in LVM between 6 and 12 months in the combined group was À7 g/m 2 (95% confidence interval (CI): À17 to þ 3 g/m 2 ).
Arterial stiffness. No differences in development over time of parameters of arterial stiffness were observed between treatment groups (Table 3 ).
Blood pressure dependency of effects on left ventricular mass index and arterial stiffness
In the whole group, the decrease in LVM index was partially (B17%) dependent on the decrease in office systolic pressure ( Table 2 ). The decrease in LVM index was independent of changes in arterial stiffness (adjustment for SAC is shown in Table 2 , other data not shown). In the whole group, the improvements of arterial stiffness were partiallydependent on the decrease in mean arterial blood pressure (Table 2) , that is, carotid DCB50%, CCB62% and EyB95%; femoral artery DCB39% and CCB73%; brachial artery DCB63% and CCB60%; and total SACB59%. Owing to small size of the individual treatment groups and the variability of the measurements, analysis of blood pressure dependency of the effects on LVM index and arterial stiffness in the individual treatment groups was not reliable. Figure 6 Boxplots of arterial stiffness estimates with median values, 25th, 75th (horizontal lines) and 5th and 90th (black circles) percentiles as vertical boxes with error bars of the total study group. GEE, generalized estimating equation Po0.01 for all variables; DC, distensibility coefficient; CC, compliance coefficient; ba, brachial artery; fa, femoral artery; cca, common carotid artery. 
Discussion
This study shows that aggressive antihypertensive therapy significantly decreases LVM index and arterial stiffness in relatively uncomplicated hypertensive type II diabetic individuals; these effects are partially mediated by blood pressure reduction. There were no significant differences between antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril. This study is the first to examine the effect of aggressive antihypertensive strategies on LVM index and arterial stiffness in hypertensive type II diabetic individuals. It is therefore difficult to compare the results with those of previous studies, which studied non-diabetic patients, 14, [28] [29] [30] [31] used monotherapy 14, [32] [33] [34] or were short-term. 16 The design of this study was meant to reflect clinical practice, in which hypertensive type II diabetic patients typically need more than one agent to achieve adequate blood pressure regulation according to current guidelines. 35 In this context, we show that aggressive antihypertensive treatment decreases LVM index and arterial stiffness, which may thus be pathways through which such treatment reduces cardiovascular risk. [36] [37] [38] In addition, our study suggests that the effects on LVM index and arterial stiffness of aggressive antihypertensive therapy based on ACE inhibitors and AT1 receptor antagonists are not superior to conventional drugs. This study was small, and we therefore cannot exclude that some differences between the groups remained undetected. However, the analyses in Table 3 , taken together, suggest that the overall effects were quite similar in the three groups.
Although mean blood pressure in our patients was 134/81 mm Hg after 12 months of treatment, the results confirm 39 that strict treatment of hypertension in type II diabetes is difficult, with B30% of patients in this study not achieving their target blood pressure even during intensive guidance. As compared to monotherapy with renin-angiotensin system inhibitors in hypertensive type II diabetic patients with a comparable baseline LVM index, 34, 40, 41 the aggressive antihypertensive strategies in our study resulted in greater reduction of LVM index (10 vs 0 to 5%). In contrast, possibly because a greater baseline LVM index is positively related to LVM index reduction, 31 ,42 monotherapy with renin-angiotensin system inhibitors in patients with established left ventricular hypertrophy and diabetes mellitus type II 33, 43 essential hypertension 29, 30 or end-stage renal failure 29 has been associated with reductions of LVM index of 11 to 13%, that is, at least similar to those in the current study. We found no data on diuretic monotherapy and LVM index in type II diabetes. At an equivalent reduction in blood pressure, we observed no significant differences in effect on LVM index between antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril, in accordance with results of antihypertensive monotherapy in essential hypertension. 30, 31, 42 Interestingly, in our study the reduction of LVM index in the hydrochlorothiazide group appeared to have reached its maximum already at 6 months, whereas in both the candesartan and the lisinopril groups, this effect seemed to continue till 12 months; we thus cannot exclude that prolonged treatment based on reninangiotensin system inhibitors may have greater effects on LVM than treatment based on hydrochlorothiazide, but further studies are needed to test this hypothesis.
In a recent meta-analysis of patients with essential hypertension, 31 there was a trend for greater reduction of LVM index with ACE inhibitors (10%) and AT1 receptor antagonists (13%) than with diuretics (8%), but, as in our study, this difference was not significant.
Taken together, these and the present data suggest that aggressive antihypertensive therapy in type II diabetes reduces LVM index more effectively than monotherapy, and that during aggressive antihypertensive therapy, there are no clear differences between strategies without and with renin-angiotensin system inhibitors.
Aggressive antihypertensive strategies were associated with improvement of all estimates of arterial stiffness. Quantitatively, these improvements appeared greater than in studies of renin-angiotensin system inhibitor monotherapy, 14, 28, 44 although comparisons are hazardous owing to differences in populations investigated (mostly non-diabetic), duration of treatment and arterial stiffness estimates used. Studies of diuretic monotherapy have yielded less consistent results, showing either no change or improvement of common carotid, femoral and brachial artery stiffness, 14, 28, 45 as well as effects similar or lesser than that of renin-angiotensin system inhibitors. 14, 28, 46 Taken together, these 14, 28, 44, 46, 47 and the current results suggest that, in the context of aggressive antihypertensive strategies, differences in effects on arterial stiffness between strategies based on hydrochlorothiazide, candesartan and lisinopril, if any, are not large. The decreases in LVM index and arterial stiffness were both partly mediated by blood pressure reduction. It therefore appears that mechanisms other than blood pressure reduction, such as interference with the renin-angiotensin system, also contribute, which contrasts with the lack of difference in reduction of LVM index and arterial stiffness between the treatment groups. A possible explanation is that the effects of blood pressure lowering and interference with the renin-angiotensin system are not additive. Unfortunately, our study did not have enough power to analyse blood pressure dependency in individual treatment groups.
The decrease in LVM index was not mediated by reduction of arterial stiffness. This is in agreement with the results of Henry et al. 48 in individuals with impaired glucose tolerance and type II diabetes, in whom the increase of LVM index was independent of increased arterial stiffness.
Our study had several limitations. First and most importantly, the groups were small, and we may have missed differences between the hydrochlorothiazide-, candesartan-and lisinopril-based treatments. However, such differences, if any, are likely to be relatively small, especially in relatively uncomplicated type II diabetic patients. Another disadvantage of the small size of our study population was that analysis of blood pressure dependency of the effects on LVM index and arterial stiffness could only be determined for the whole study group and not for the individual treatment groups.
Second, because of the variability of office blood pressures, we may to some extent have underestimated the effect of the blood pressure decrease on the outcome measures. As LVM index and arterial stiffness in type II diabetes tend to increase with time, we probably in general have underestimated the (beneficial) effects of aggressive antihypertensive treatment on these variables.
Finally, we did not include a placebo-treated control group, for obvious reasons.
In conclusion, aggressive antihypertensive treatment based on hydrochlorothiazide, candesartan or lisinopril, although difficult to achieve, results in substantial reductions of LVM index and arterial stiffness in relatively uncomplicated hypertensive type II diabetic individuals. We observed no significant differences in effects between the three different antihypertensive strategies, and therefore conclude that strategies based on renin-angiotensin system inhibitors, in this respect, may not be superior to conventional (i.e., diuretic-based) strategies to achieve strict target pressures in type II diabetes.
